Salarius Pharmaceuticals, Inc.
NASDAQ: SLRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Frederick E. Pierce
- Employees
- 2
- Headquarters
- Houston, United States
- IPO year
- 2015
- Market cap
- $4.9M
- Website
- https://www.salariuspharma.com
Loading SLRX…
Loading profile data…Frequently asked questions about SLRX
What does Salarius Pharmaceuticals, Inc. (SLRX) do?
Salarius Pharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to advancing epigenetic-based cancer therapies. Its flagship investigational product, Seclidemstat (SP-2577), a small molecule inhibitor, is currently undergoing Phase I/II clinical evaluation. This compound is being developed to treat Ewing sarcoma and a range of ad...
Where does SLRX trade?
Salarius Pharmaceuticals, Inc. (SLRX) trades on the NASDAQ Capital Market.
What sector is SLRX in?
Salarius Pharmaceuticals, Inc. (SLRX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Salarius Pharmaceuticals, Inc.?
Frederick E. Pierce is the chief executive officer of Salarius Pharmaceuticals, Inc. (SLRX).
Where is Salarius Pharmaceuticals, Inc. headquartered?
Salarius Pharmaceuticals, Inc. is headquartered in United States.
Does SLRX pay a dividend?
Salarius Pharmaceuticals, Inc. (SLRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SLRX go public?
Salarius Pharmaceuticals, Inc. (SLRX) completed its initial public offering in 2015.